At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 72 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Cisplatin 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-labeled, Randomized, Multicenter Phase III Study of Adjuvant Chemotherapy Comparing Bevacizumab Plus Cisplatin With Cisplatin Regimen in Malignant Pleural Effusion of Advanced Stage Non-Small-Cell Lung Cancer Patients
In Brief
A Phase 3 clinical trial evaluating Bevacizumab and Cisplatin for Malignant Pleural Effusion. Completed, enrolled 72 participants across 1 site.
Detailed Summary
To determine the efficacy and Safety of intrapleural Bevacizumab and cisplatin as a treatment for malignant pleural effusions (MPE) in patients with non-small cell lung cancer (NSCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Pleural Effusion
CountriesChina
CollaboratorsRoche Pharma AG
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2009
Primary CompletionJun 2012
First PostedAug 2012
Study CompletionOct 2012
TodayJul 2026
First PostedAug 10, 2012
Enrollment StartAug 1, 2009
Primary CompletionJun 1, 2012
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.9 years ago
Interventions
Bevacizumabdrug
Bevacizumab300mg\&Cispltin30mg by intrapleural administration of each 2 week
Cisplatindrug
Cisplatin 30mg,intrapleural administration,each 2 week